Drug profile · INN
bedaquiline fumarate
SIRTURO
bedaquiline fumarate (SIRTURO) is a atp synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — bedaquiline fumarate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
bedaquiline fumarate (SIRTURO) is a atp synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
ATP synthase inhibitor
Primary target: ATP synthase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Frequently asked questions
What is bedaquiline fumarate?
bedaquiline fumarate (SIRTURO) is a atp synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for bedaquiline fumarate?
SIRTURO is a marketed brand name for bedaquiline fumarate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bedaquiline fumarate?
bedaquiline fumarate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.